Overview
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer previously treated with crizotinib. This is because Roche did not provide an evidence submission.
Last reviewed: 29 March 2017
Next review: We will review this decision if the company decides to make a submission